Cereno, Abbott Team Up to Measure Lung Blood Pressure in New Trial
Cereno Scientific is planning to begin a Phase 2 clinical trial of CS1 — the company’s lead therapy candidate for pulmonary arterial hypertension (PAH) — this September, following clearance from the U.S. Food and Drug Administration (FDA). The upcoming trial will use Abbott‘s CardioMEMS HF System, a…